An open-label phase I/II study of XIAP antisense AEG35156 administered to patients with refractory/relapsed AML in combination with chemotherapy.

Trial Profile

An open-label phase I/II study of XIAP antisense AEG35156 administered to patients with refractory/relapsed AML in combination with chemotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2012

At a glance

  • Drugs AEG 35156 (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aegera Therapeutics
  • Most Recent Events

    • 17 Dec 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top